At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
PF-04950615 (RN316) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.
In Brief
A Phase 2 clinical trial evaluating Placebo and PF-04950615 (RN316) for Hypercholesterolemia and Dyslipidemia. Completed, enrolled 46 participants across 35 sites in 2 countries.
Detailed Summary
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionApr 2012
Study CompletionJun 2012
TodayJul 2026
First PostedMay 9, 2011
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.1 years ago
Interventions
Placeboother
An infusion lasting approximately 60 minutes
PF-04950615 (RN316)drug
An infusion lasting approximately 60 minutes
PF-04950615 (RN316)drug
An infusion lasting approximately 60 minutes